綠葉製藥(02186.HK)：山東博安獲戰投6.82億元
格隆匯1月4日丨綠葉製藥(02186.HK)公佈，山東博安（公司的間接附屬公司）、原博安股東、公司及投資者（包括甲組投資者及乙組投資者）訂立認購協議，據此山東博安有條件地同意發行，而投資者有條件地同意認購股權，該等股權佔完成後的山東博安經擴大全部註冊資本的12.32%，注資總額為現金人民幣6.82億元。
於完成後，山東博安的註冊資本將由人民幣4.08億元增加至人民幣4.65億元，並由山東綠葉（公司的間接全資附屬公司）持有約77.44%，由博安員工持股計劃實體持有10.23%，及由投資者合共持有12.32%。山東博安將繼續為公司的附屬公司，而山東博安的財務業績將繼續入賬及綜合計入集團的財務業績。
據悉，根據乙組認購協議，山東博安有條件地同意發行，而乙組投資者有條件地同意認購股權，該等股權佔完成後的山東博安經擴大註冊資本的9.79%（假設於完成前山東博安將不會發行其他股權），注資總額為現金人民幣5.42億元。
山東博安於2013年成立，是一家全面綜合性生物製藥公司。其專門從事治療用抗體開發，專注於腫瘤、免疫性、疼痛及內分泌疾病。在過去幾年，山東博安在抗體生產、先導優化物、細胞系建立、工藝開發、技術轉讓、中試生產及商業化生產方面積累了豐富的經驗。山東博安的抗體發現活動圍繞四個平台展開，即全人抗體轉基因小鼠及噬菌體展示技術、雙特異性T細胞銜接系統技術、抗體偶聯技術及納米抗體平台。
認購事項的所得款項將用作山東博安主營業務的補充營運資金。認購事項的資金可減緩山東博安業務發展帶來的財務壓力，增強山東博安抵禦風險及保持市場競爭力的能力，促進山東博安的長期穩定發展。
此外，引進戰略投資者預期將為山東博安的發展與山東博安搶佔行業領先地位的能力帶來協同作用。鑑於山東博安的業務發展、資金需求及未來資本市場規劃，董事認為認購事項符合公司及其股東的整體利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
